Recent News

• 03.27.2026 - Pinnacle 21 Community or Enterprise: How to decide which is right for your study
• 03.27.2026 - How Bayesian Design Is Reshaping Clinical Development
• 03.27.2026 - Where Did the 80-125% Bioequivalence Criteria Come From?
• 03.26.2026 - Integrated PK/PD Modeling and Machine Learning to Support CNS Compound Selection
• 03.26.2026 - Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics
• 03.26.2026 - Shaping the Future of Medical Writing: Key Themes for 2026
• 03.26.2026 - The Next Lap in Global Regulatory Submission Speed: Advanced Approaches to Excellence and Acceleration
• 03.25.2026 - Portfolio Prioritization for Large and Small Pharma Using Early-Stage Biosimulation
• 03.25.2026 - An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors
• 03.25.2026 - Model-Based Patient Selection and Dosing Strategies for HRAS and PIK3CA Dysregulated HNSCC: A QSP Model for Alpelisib and Tipifarnib Combination

Recent Filings

• 03.26.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors